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a-human atrial natriuretic peptide (a-h-ANP) was purified to homogeneity from human plasma of healthy 
adults in a three-step rocedure including immunoattinity chromatography on immobilized monoclonal 
anti-a-h-ANP antibody (moab). A single peak of immunoreactivity was obtained after final reversed-phase 
HPLC and the amino acid sequence of the isolated material was identical to that of synthetic t-h-ANP. 
No further atrial peptides could be detected although the moab reacts with all biologically active peptides. 
It is therefore concluded that ~t-h-ANP is the only form of ANP circulating in human plasma. 
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1. INTRODUCTION 
Atrial natriuretic peptides (ANP) are a family of 
peptides possessing natriuretic, diuretic, and 
vasorelaxant properties [1]. Furthermore, inhibi- 
tion of aldosterone synthesis [2] and renin release 
have been well documented [3]. The peptides or 
probably their precursors are stored in specific 
secretory granules in mammalian atrial cardiocytes 
[4]. ANP are secreted into the blood stream, the 
extension of the atria being the only known 
stimulus o far [5]. They have been isolated and se- 
quenced from atria of several mammalian species 
(e.g. man, rat, bovine) [6]. The predominant low- 
Mr species purified from human atrial is o~-human 
ANP (ot-h-ANP). So far there exists only indirect 
evidence as to whether this is the only circulating 
form of ANP [8-11]. Here, we describe the 
purification of atrial peptides from human plasma 
by immunoaffinity chromatography and reversed- 
phase HPLC. The isolated material was 
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homogeneous in nature and sufficient for amino 
acid sequence analysis. 
2. MATERIALS AND METHODS 
Synthetic atrial peptides, rat ANP fragments 
(13-28) and (18-28), and human ANP fragment 
(7-28) were purchased from Novabiochem 
(Switzerland) or Peninsula (USA). 
125I-labelled rat ANP (1-28) was obtained from 
Amersham (England) or by iodination of rat ANP 
(I-28) using the chloramine T method [7]. Leu- 
enkephalin, [IleS]angiotensin II, [ArgS]vasopres - 
sin, substance P, y-MSH, and bovine serum 
albumin were from Sigma (FRG). Bradykinin, 
ACTH (porcine), aldosterone and insulin (rat) 
were from Serva (FRG). 
2.1. Generation of  monoclonal antibodies 
ce-h-ANP was coupled to keyhole limpet hemo- 
cyanin (KLH, Pacific Biomarine Supply, USA) us- 
ing 0.25°7o glutaraldehyde. Female Balb/C mice 
(Moellegard, Denmark) were injected with 100/zg 
of antigen once in complete Freund's adjuvant in- 
traperitoneally, followed by a second in- 
traperitoneal injection 2 weeks later. 3 days before 
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cell fusion the animals were finally injected in- 
travenously with 100/zg antigen in phosphate- 
buffered saline. Spleen cells of immunized mice 
were fused with the myeloma cell line 
X 63-AG 8.653 according to standard techniques 
[15]. Clone cells were used to produce ascitic fluid 
in male Balb/C mice [14]. 
2.2. Radioimmunoassay 
Determination of ANP was performed in RIA 
buffer (0.02 M Na2HPO4/NaH2PO4, 0.15 M 
NaCI, 0.01070 thimerosal, 0.1°7o gelatin, 0.01°70 
BSA, 0.107o Triton X-100; pH 7.4). 50/zl 125I- 
atriopeptin III (approx. 6000 cpm) was added to 
350-/zl samples in RIA buffer followed by 100/zl 
anti~-h-ANP ascites fluid (dilution 1:2 Mio.). 
Samples were incubated for 16 h at 4°C. Separa- 
tion of antibody-bound and free peptide was per- 
formed by adding 800/zl of a charcoal suspension 
(0.02 M Na2HPO4/NaH2PO4, 2070 Norit-A, 
0.02°70 dextran 60, 0.1°70 BSA, 10 mM Na2EDTA; 
pH 7.4). The sample was vigorously mixed, al- 
lowed to stand for 20 min and finally centrifuged 
(5 min, 3600 × g). Radioactivity ofthe supernatant 
was determined in an LKB 1271 RIA gamma- 
counter. 
2.3. Plasma extraction 
10 1 of human plasma containing approx. 0.8/~g 
ANP immunoreactivity were chilled immediately 
after collection. To prevent proteolytic degrada- 
tion plasma was supplemented with EDTA, 
phenylmethylsulfonyl fluoride (PMSF), aprotinin 
and bacitracin. 
RP 18 adsorbent resin (Merck, FRG) was added 
and the suspension stirred gently for 30 rain. The 
supernatant was discarded and the reversed-phase 
material was washed with 2o7o acetonitrile 
(CH3CN) in 0.1 °7o trifluoroacetic acid (TFA) and 
10°70 CH3CN in 0.1°70 TFA. The peptide fraction 
was eluted with 50o7o CH3CN in 0.1 o7o TFA. Frac- 
tions of the washing and elution steps were 
lyophilized and assayed for immunoreactivity. 
2.4. Immunoaffinity chromatography 
Anti-cr-h-ANP moab was purified from mouse 
ascites fluid by affinity chromatography on im- 
mobilized cr-h-ANP. 35 mg purified moab were 
coupled to 7 ml CNBr-activated Sepharose 4B 
(Pharmacia, Sweden) according to the manufac- 
turer's procedure. The RP 18 eluate containing 
ANP immunoreactivity was dissolved in 10 ml of 
0.2 M Na2HPO4/NaH2PO4 (pH 7.2) and applied 
to the immunoaffinity column (1 × 7 cm) at 
8 ml/h, washed with 0.1 M CH3COOH and eluted 
with 0.1 M CH3COOH/0.5 M NaC1. 4-ml frac- 
tions were collected and assayed for ANP im- 
munoreactivity. Immunoreactive material was 
desalted on RP 18 cartridge and lyophilized. 
2.5. Reversed-phase chromatography 
Final purification was achieved by HPLC on 
RP 18 Ultrasphere ODS (Beckman Instruments, 
USA) using a gradient from 2°70 CH3CN to 60°70 in 
0.1°70 TFA over 30 min. Fractions of 0.5 ml were 
collected, assayed for immunoreactivity, and 
lyophilized. 
2.6. Amino acid sequence determination 
The peptide was solubilized in 30/zl TFA. The 
sample was applied to a glass-fiber filter which was 
pretreated with 3 mg polybrene. Sequence analysis 
was performed using a gas-phase protein sequencer 
from Applied Biosystems (USA) [13]. 
3. RESULTS AND DISCUSSION 
3.1. Properties of the l lA-Al l  anti-oe-h-ANP 
moab 
The moab shows complete crossreactivity with 
rat ANP I, II, and III, rat ANP (1-28) and human 
ANP fragment (7-28) while there is no inhibition 
of 125I-ANP binding by rat ANP fragments 
(13-28), (18-28) and (1-11) (fig. 1). These findings 
suggest hat the moab recognizes an epitope in- 
cluding the disulfide bridge and the surrounding 
amino acids Cys 7 and Asn 24. Due to these proper- 
ties all biologically active ANP species are equally 
well recognized. There is no crossreactivity of the 
moab employed with a variety of other circulating 
peptides and renal active hormones ([IleS]angioten - 
sin II, Leu-enkephalin, substance P, aldosterone, 
ACTH [porcine], bradykinin, y-MSH, insulin 
[rat], [Argalvasopressin, renin [porcine]) up to the 
micromolar range. 
3.2. Purification procedure 
In the first purification step (RP 18 batch) all 
immunoreactive material was eluted with 50°7o 
acetonitrile (recovery 72°7o). The l lA-All moab 
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Fig.1. Crossreactivity of cr-h-ANP (1-28) (A), r-ANP I 
(x), r-ANP II (o), r-ANP III (m), h-ANP fragment 
(7-28) (o), and h-ANP fragment (13-28) (A) with ~25I- 
r-ANP III. Inhibition of binding was determined as 
described in section 2. 
was used for affinity chromatography of the pep- 
tide extracts resulting in an 8000-fold purification 
in a single step (fig.2). Reversed-phase HPLC 
yielded final separation of ANP immunoreactivity 
from contaminating peptides (fig.3). The HPLC 
fractions (40pmol )  were then submitted to 
NH2-terminal sequence analysis using a gas-phase 
sequencer. The sequence of ~-h-ANP (1-28) was 
obtained. 
Our findings are consistent with earlier reports 
suggesting that oe-h-ANP is the circulating atrial 
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Fig.2. Affinity chromatography on anti-ANP-moab- 
Sepharose-4B. ot-h-ANP-containing fractions of the 
RP 18 batch procedure were applied to the affinity 
column and eluted stepwise by 0.1 M CH3COOH and 
0.1 M CH3COOH/0.5 M NaCl (flow rate 8 ml/h). 
Aliquots of each fraction were assayed for ANP 
immunoreactivity. Results are shown by bars. The 
continuous line indicates A2s0. 
peptide in humans [8-11]. This study, however, 
presents the first data on the amino acid sequence 
of material isolated from human plasma, whereas 
former conclusions concerning the nature of cir- 
culating ANP have only been drawn by com- 
parison of retention times in reversed phase 
chromatography. 
Besides oe-h-ANP we did not find any other 
ANP species in blood of healthy adults. Several 
groups described the existence of circulating atrial 
peptides horter than h-ANP [11,12]. In contrast 
to these results we could not identify any shorter 
forms of ~r-h-ANP although the crossreactivity of
the anti-ANP moab would have allowed the detec- 
tion of shorter forms of biologically active ANP 
[14]. 
Furthermore, no extended forms of ce-h-ANP 
(pro-h-ANP) were detected although the moab 
also reacts with pro-h-ANP extracted from atrial 
A) (x-HUMAN ANP (1-28) 
B) EXTRACT FROM HUMAN 
PLASMA AFTER AFFINITY 
CHROMATOGRAPHY 
........ rill% 
Fig.3. HPLC on RP 18. (A) A215 of 10/zg synthetic u-h- 
ANP (1-28). (B) The upper trace shows A215 of the 
affinity-purified oz-h-ANP from human plasma. 
Aliquots of each 1 ml fraction were assayed for ANP 
immunoreactivity. Results are shown by bars. Flow rate: 
1 ml/min. Solvent A: 0.1% TFA. Solvent B: acetonitrile 
gradient, 2-60% in 30 min. 
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tissue as demonstrated by Western blotting (not 
shown). 
Assuming that ANP is stored in the atrial 
granula as a prohormone, the secretion mechanism 
as well as the proteolytic activating step await fur- 
ther investigation. 
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